Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6398615 | 0.84 | USP30 (0.57) | KMT2AMEN1LMNANPC1RAB9A | |
| SCHEMBL6399782 | 0.82 | L3MBTL1 (0.54) | L3MBTL1KMT2AMEN1LMNANPC1 | |
| SCHEMBL1021727 | 0.81 | FAAH (0.62) | KMT2AMEN1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL6399092 | 0.81 | L3MBTL1 (0.53) | L3MBTL1KMT2AMEN1LMNANPC1 | |
| SCHEMBL19896563 | 0.76 | USP30 (0.53) | L3MBTL1KMT2ALMNACTDSP1TDP1 | |
| SCHEMBL19896562 | 0.76 | USP30 (0.53) | L3MBTL1KMT2ALMNACTDSP1TDP1 | |
| SCHEMBL20658792 | 0.76 | FAAH (0.51) | KMT2AMEN1LMNAGAARAB9A | |
| SCHEMBL21257402 | 0.76 | SMYD3 (0.78) | L3MBTL1KMT2AMEN1LMNANPC1 | |
| SCHEMBL995119 | 0.75 | POLB (0.66) | KMT2AMEN1NPC1RAB9A | |
| SCHEMBL2636547 | 0.75 | MEN1 (0.68) | L3MBTL1KMT2AMEN1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176724-A1 | Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors | GLAXO GROUP LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
| EP-1476161-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068236-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176724-A1 | Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors | HTR5A, HTR2C, HTR3C | L3MBTL1 2549/4885KMT2A 2269/4885HTT 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.